Drug Trial Radar · NCT02296190
Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm
Last checked: Nov 20, 2026Latest source record: Dec 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
199
Actual
Start
Mar 27, 2015
Primary completion
Dec 2016
Study completion Dec 2016
Sponsor
- Lead sponsor
- Milestone Pharmaceuticals Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Medpace, Inc.
- First posted
- Nov 20, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to demonstrate the superiority of at least 1 dose of intranasal (IN) MSP-2017 (Etripamil) over placebo in terminating PSVT induced in an electrophysiology (EP) laboratory.
Conditions
- Paroxysmal Supraventricular Tachycardia (PSVT)
Interventions
EtripamilDrug
intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
PlaceboDrug
intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Percentage of Subjects Successfully Converted From PSVT to Sinus Rhythm Within 15 Minutes of Study Drug AdministrationTime frame: Within 15 minutes of study drug administration
Locations
30 sites in 2 countries. Site status is shown where the registry gives one.
Arizona Heart Rhythm Center
Phoenix, Arizona
Mayo Clinic Arizona
Phoenix, Arizona
Mercy General Hospital
Sacramento, California
South Denver Cardiology Associates
Littleton, Colorado
Medstar Washington Hospital Center
Washington D.C., District of Columbia
Memorial Hospital Jacksonville
Jacksonville, Florida
Mayo Clinic Jacksonville
Jacksonville, Florida
Northside Hospital
St. Petersburg, Florida
University of South Florida Health South Tampa Center
Tampa, Florida
Piedmont Atlanta Hospital
Atlanta, Georgia
Emory University Hospital
Atlanta, Georgia
Iowa Heart Center
West Des Moines, Iowa
University of Kansas Medical Center
Kansas City, Kansas
MedStar Health Research Institute
Baltimore, Maryland
Mayo Clinic
Rochester, Minnesota
Aultman Hospital Cardiology Clinical Trials
Canton, Ohio
University of Cincinnati Medical Center Division of Cardiovascular Diseases
Cincinnati, Ohio
ProMedica Toledo Hospital
Toledo, Ohio
Great Lakes Medical Research, LLC
Willoughby, Ohio
Black Hills Cardiovascular Research
Rapid City, South Dakota
Texas Cardiac Arrhythmia Research Foundation
Austin, Texas
Baylor St. Luke's Hospital
Houston, Texas
Houston Methodist Hospital
Houston, Texas
University of Virginia Medical Center
Charlottesville, Virginia
Centra Stroobants Cardiovascular Center
Lynchburg, Virginia
Sentara Norfolk General Hospital
Norfolk, Virginia
Sunnybrook Health Sciences Center
Toronto, Ontario, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
The Montreal Heart Institute
Montreal, Quebec, Canada
CHUM Hotel Dieu
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.